Skip to Content
Menu
About
Science
EDO Platform
Scientific Publications
Pipeline
Overview
Clinical Trials
Expanded Access Policy
Community
Careers
Investors
News
Contact
Advancing the Use of Peptide-Conjugated Oligonucleotides to Target Neuromuscular Disorders: Enhanced Delivery Oligonucleotides for DMD and DM1
Post navigation
Previous:
CONNECT2-EDO51: A Phase 2 placebo-controlled study to evaluate PGNEDO51 safety and efficacy in people with Duchenne amenable to exon 51 skipping
Next:
Mechanistic characterization of enhanced delivery oligonucleotide (EDO) platform
